Clinical concordance data for AML and NHL along with preclinical data on targeting KRAS to be presented
KYAN Technologies Pte Ltd (“KYAN”), an innovative small data AI biotech company, today announced that it will present three posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place in Boston, MA from October 15 to October 19, 2023. The posters will showcase and further validate the preclinical and clinical capabilities of the Optim.AI™ platform which takes a combinatorial approach to functional precision oncology. “Our mission of bridging the cancer care gap becomes more fully realized as we close the gap between genotype and phenotype, moving from precision medicine to functional precision medicine,” said Hugo Saavedra, founder and Chief Executive Officer of KYAN. “The results of our studies demonstrate the potential of Optim.AI™ to target more prevalent and untapped KRAS mutations, and the next evolution of our platform in adding immunotherapies for guided patient treatment.”
Details on the posters presentations are as set forth below.
ABSTRACT TITLE: Clinical evaluation of a functional combinatorial precision medicine platform to predict combination immunotherapy responses in hematological malignancies
POSTER NUMBER: A125
ABSTRACT TITLE: Identification of therapeutic drug combinations targeting KRAS
POSTER NUMBER: A127
ABSTRACT TITLE: Analytical and clinical evaluation of a functional combinatorial precision medicine platform
POSTER NUMBER: A128
POSTER SESSION: A
SESSION DATE/TIME: Thursday, October 12 | 12:30 pm-4:00 pm
SESSION LOCATION: Level 2, Exhibit Hall D